Home › Blog › Weight Loss › Mounjaro Dosing Schedule
Mounjaro Dosing Schedule UK 2026: Every Dose From 2.5mg to 15mg — When to Escalate, When to Stay, and What to Expect
Mounjaro at Slinic — Every Dose Reviewed Before Dispatch
Free monthly check-in · Every escalation clinically approved · From £139/pen · No subscription
- ✅ 2.5mg £139 · 5mg £165 · 7.5mg £225 · 10mg £255 · 12.5mg £275 · 15mg £285
- ✅ Every dose increase reviewed by a registered Slinic prescriber
- ✅ Side effect management, diet advice, and progress monitoring included
Overview: The Mounjaro Dosing Schedule
Mounjaro (tirzepatide) is a once-weekly injection given in six escalating doses — from 2.5mg (initiation) to 15mg (maximum maintenance). The dose escalation protocol is not arbitrary: it exists because starting at higher doses produces significantly worse gastrointestinal side effects. Gradual escalation allows the body to adapt to tirzepatide’s GLP-1 and GIP receptor activation before each increase.
Understanding the schedule — what each dose does, when to move to the next, and when to stay longer — is one of the most important things any Mounjaro patient can know. At Slinic, every dose escalation is reviewed by a registered prescriber before being approved. This guide explains what that review considers and how to get the most from every stage of your treatment.
The Complete Mounjaro Dosing Schedule
| Dose | Treatment stage | Minimum duration | Slinic price | Purpose |
|---|---|---|---|---|
| 2.5mg | Starting dose | 4 weeks | £139.00 | Initiation — body adaptation. NOT a therapeutic weight loss dose. |
| 5mg | First escalation | 4 weeks | £165.00 | First therapeutic dose — significant appetite suppression begins |
| 7.5mg | Mid escalation | 4 weeks | £225.00 | Continued escalation — weight loss accelerates |
| 10mg | Upper escalation | 4 weeks | £255.00 | High efficacy — many patients maintain here (19.5% average weight loss) |
| 12.5mg | High maintenance | 4 weeks | £275.00 | Near-maximum dose — approaching full efficacy |
| 15mg | Maximum dose | Ongoing | £285.00 | Maximum licensed dose — 22.5% average weight loss in SURMOUNT-1 |
All Slinic prices + £4.99 delivery. No subscription. Free monthly check-ins. Subject to clinician approval at each stage.
Dose-by-Dose: What to Expect at Every Stage
What it is for: The 2.5mg dose is not a therapeutic weight loss dose. It is a pharmacological “on-ramp” — allowing your body to adapt to tirzepatide before the doses that produce significant effects. Think of it as your body learning the language of the medication.
What most patients experience: Mild appetite reduction by week 2. Some nausea in the first few days — usually mild and passing. Modest weight change (1–3 kg typical). The “food noise” — constant background thoughts about food — may begin to quieten.
When to escalate: After 4 weeks at 2.5mg, your Slinic prescriber will review your response and tolerance. If side effects are manageable (or absent), escalation to 5mg is typically approved. If nausea was significant, a further week at 2.5mg may be recommended.
What it is for: The 5mg dose is the first dose at which significant clinical effects occur for most patients. Average weight loss in SURMOUNT-1 at 5mg was approximately 15% over the full trial period — the 5mg arm was not followed at maintenance but the dose demonstrates meaningful efficacy.
What most patients experience: Significant appetite reduction — many patients describe eating half of normal portions and feeling genuinely satisfied. The “food noise” is noticeably quieter. Nausea returns briefly in the first days of the new dose and typically settles within 5–7 days. Weight loss typically 2–5 kg in month 2.
When to escalate: After 4 weeks at 5mg, if you are tolerating it well and have not yet reached your weight loss goal, escalation to 7.5mg is typically appropriate. Some patients who are already losing well at 5mg with minimal side effects may remain here longer by discussion with their Slinic clinician.
What most patients experience: Weight loss is now clearly visible — face, waist, and upper body typically show changes. Energy levels improving. Clothing fitting differently. Side effects from the 7.5mg dose typically peak in the first week then reduce. For many patients this is the first dose where the transformation feels real.
When to escalate vs stay: If progress is strong at 7.5mg and side effects are well managed, continue to 10mg at week 13. If nausea or GI side effects were significant at 7.5mg, remaining at this dose for an additional 4 weeks before escalating is clinically appropriate — slower escalation produces better tolerability.
What it is for: Many patients find 10mg to be their optimal maintenance dose — producing average weight loss of approximately 19.5% in SURMOUNT-1 with manageable side effects. It is worth discussing with your Slinic clinician whether 10mg is the right maintenance dose for you, rather than automatically escalating to 12.5mg or 15mg.
What most patients experience: Significant cumulative weight loss (typically 10–17 kg by month 4). Physical activity significantly easier. Joint pain often reduced. Many patients achieving 15% of starting body weight lost by this stage.
Staying at 10mg — when it makes sense: If you are losing weight consistently and tolerating 10mg well, there is no clinical requirement to escalate further unless your progress plateaus. The cost saving (£255/month vs £285/month for 15mg) is also a relevant practical consideration for many patients.
What most patients experience: Continuing weight loss at high levels. Most patients at this stage have lost 15–20% of starting body weight. Cardiometabolic markers — blood pressure, cholesterol, blood sugar — typically showing significant improvement. Side effects from 12.5mg usually minimal if 10mg was well tolerated.
When to escalate vs stay: If weight loss has slowed significantly at 12.5mg and you have not reached your goal, escalation to 15mg is appropriate. If results are still strong and you are not experiencing problematic side effects, some patients remain at 12.5mg as their maintenance dose.
What it is for: The maximum licensed dose — the dose that produced average weight loss of 22.5% in SURMOUNT-1 at 72 weeks. Not all patients need to reach 15mg. Those who do should expect continued weight loss accumulation over the following 6–12 months, not immediate maximum results.
What most patients experience: Maximum appetite suppression. Side effects at the established 15mg dose are typically minimal after the brief adjustment period at the new dose. The 22.5% average weight loss is measured at 72 weeks — patients reaching 15mg in month 5 still have over a year of result accumulation ahead of them.
When to Escalate and When to Stay Longer
The standard protocol escalates by one dose every 4 weeks. But this is a minimum, not a mandate. Here is the clinical framework Slinic uses to determine whether to escalate on schedule or stay at a dose longer.
| Situation | Slinic recommendation | Rationale |
|---|---|---|
| 4 weeks completed, good tolerance, weight loss on track | Escalate to next dose | Standard protocol — progress without undue side effect burden |
| 4 weeks completed but nausea still present | Stay at current dose for another 4 weeks | Body needs more adaptation time — escalating too fast amplifies side effects |
| 4 weeks completed, weight loss strong, no side effects | Discuss whether current dose is optimal maintenance | Not all patients need 15mg — many achieve their goals at 10mg or 12.5mg |
| Weight loss plateaued at current dose | Escalate to next dose | Plateau at a sub-maximum dose is the clearest signal to escalate |
| Side effects unacceptable at current dose | Consider reverting to previous dose, not stopping | Previous dose may be tolerable and still therapeutic |
| Surgery planned | Do not escalate — discuss pause protocol | Mounjaro requires stopping before elective surgery. See your Slinic clinician. |
Missing a Dose: What to Do
| When you remember the missed dose | What to do |
|---|---|
| Within 4 days of your usual injection day | Take the missed dose as soon as possible. Then resume your usual weekly schedule. |
| More than 4 days after your usual injection day | Skip the missed dose. Take your next dose on the originally scheduled day. Do not double up. |
| You have missed more than 4 weeks of doses | Contact your Slinic clinician before restarting. You will need to restart at 2.5mg. See our restart guide. |
Injection Technique: How to Use the Mounjaro KwikPen
- Remove from fridge 30 minutes before — allow to reach room temperature. Cold medication causes more discomfort.
- Choose your injection site — abdomen (at least 2 inches from navel), outer thigh, or upper arm. Rotate each week — never the same spot twice consecutively.
- Clean the site — alcohol wipe, allow to dry.
- Attach the pen needle — needles are not pre-attached. Use a new needle for every injection.
- Remove the cap — outer cap first, then inner cap.
- Pinch the skin gently — hold the pen at 90 degrees to the skin.
- Press and hold for 10 seconds — press the button firmly. Hold for a full 10 seconds to ensure complete dose delivery.
- Dispose of needle immediately — in your sharps bin. Never re-use needles.
Mounjaro Storage: The Complete Guide
| Situation | Storage requirement | Duration |
|---|---|---|
| Unopened pens (not yet started) | Refrigerator 2–8°C | Until expiry date |
| Opened pen (already used once) | Room temperature up to 30°C | Up to 21 days |
| Room temperature storage | Keep below 30°C, out of direct sunlight | Up to 21 days from first use |
| Travelling with Mounjaro | Insulated bag with ice packs for journeys over 2 hours | Maintain 2–8°C for unopened pens |
Do not freeze Mounjaro. Do not use a pen that has been frozen. Do not use a pen past its expiry date. Slinic delivers all Mounjaro in certified cold-chain packaging maintaining 2–8°C throughout transit.
Finding Your Optimal Maintenance Dose
One of the most important — and underappreciated — aspects of Mounjaro treatment is that the right maintenance dose is not necessarily 15mg. Here is the clinical framework for finding your personal optimal dose.
You may not need 15mg if:
- You are achieving consistent, ongoing weight loss at 10mg or 12.5mg
- You have already reached or are close to your weight goal
- Side effects at 12.5mg were more significant than at 10mg
- Your Slinic clinician assesses that your results at the current dose are clinically satisfactory
You should escalate to 15mg if:
- Weight loss has clearly plateaued at your current dose
- You have not yet achieved 15% of starting body weight lost after 6 months on 12.5mg
- Your Slinic clinician assesses that you are tolerating the current dose well and would benefit from further escalation
Mounjaro Dosing for Type 2 Diabetes
Mounjaro is also licensed for type 2 diabetes management in the UK. The dosing schedule for T2D is the same as for weight management — starting at 2.5mg and escalating by 2.5mg every 4 weeks to a maximum of 15mg. The key difference for T2D patients is that blood sugar may improve rapidly, requiring dose adjustments to insulin or sulphonylureas to prevent hypoglycaemia. Coordinate with your diabetes team or GP throughout escalation if you are on insulin or sulphonylureas.
Stopping Mounjaro: The Right Protocol
There are several situations where Mounjaro should be stopped, temporarily paused, or dose-reduced. Here is the clinical framework:
| Situation | Action | When to restart |
|---|---|---|
| Elective surgery (general anaesthetic) | Stop Mounjaro at least 1 week before surgery (some anaesthetists prefer 2–4 weeks — check with your surgeon) | After full recovery — restart at 2.5mg if away more than 4 weeks |
| Pregnancy (planned or discovered) | Stop immediately. Must be stopped at least 4 weeks before conception. | Do not restart during pregnancy or breastfeeding |
| Acute pancreatitis suspected | Stop immediately. Seek urgent medical attention. | Do not restart — absolute contraindication after confirmed pancreatitis |
| Severe GI side effects | Contact Slinic before stopping — dose reduction usually preferred | After side effects resolved — restart at previous dose |
| Financial pause | Pause is clinically acceptable. Contact Slinic before restarting. | Restart at lower dose than you stopped at if away more than 4 weeks. See restart guide. |
Mounjaro Dosing vs Wegovy Dosing: Comparison
| Mounjaro dose | Equivalent Wegovy stage | Typical week | Slinic Mounjaro price | Slinic Wegovy equivalent |
|---|---|---|---|---|
| 2.5mg (start) | 0.25mg (start) | Weeks 1–4 | £139.00 | £99.99 |
| 5mg | 0.5mg | Weeks 5–8 | £165.00 | £109.99 |
| 7.5mg | 1mg | Weeks 9–12 | £225.00 | £114.99 |
| 10mg | 1.7mg | Weeks 13–16 | £255.00 | £159.99 |
| 15mg (maintenance) | 2.4mg (maintenance) | Week 21+ | £285.00 | £209.99 |
Every Slinic Dose Increase Is Clinically Reviewed Before Dispatch
Monthly check-in · Dose management · Side effect review · Diet guidance — all included free
- ✅ 2.5mg £139 · 5mg £165 · 7.5mg £225 · 10mg £255 · 12.5mg £275 · 15mg £285
- ✅ Every escalation requires clinician approval — protecting your safety
- ✅ GPhC No. 1033729 · NHS-contracted · No subscription
Week-by-Week Guide: Your First 24 Weeks on Mounjaro
Beyond the dose stages, here is a granular week-by-week guide to the first 24 weeks of Mounjaro treatment — what most patients experience, and what your Slinic clinician is monitoring at each point.
| Week | Dose | What most patients experience | Slinic monitoring focus |
|---|---|---|---|
| 1 | 2.5mg | First injection. Possible mild nausea day 1–3. Subtle appetite reduction beginning. | Injection technique confirmed. Baseline weight recorded. Side effects discussed. |
| 2 | 2.5mg | Appetite reduction more consistent. Food noise quieter. Weight may drop 1–2 kg from baseline. | Side effect check. Diet review. |
| 3–4 | 2.5mg | Body adapting. Nausea usually resolved. Eating noticeably less. Modest weight loss (1–3 kg total). | Month 1 check-in: tolerance and early response. Decision on 5mg escalation. |
| 5 | 5mg (if escalated) | First dose of new pen. Brief return of nausea — typically 3–7 days. Appetite suppression significantly stronger. | Escalation approved. Side effect management guidance provided. |
| 6–8 | 5mg | “Food noise” markedly reduced. Eating half-normal portions. Weight loss 2–5 kg this month. Energy improving. | Month 2 check-in. Weight progress review. Protein intake assessment. |
| 9 | 7.5mg (if escalated) | Third dose escalation. Brief GI effects — usually shorter than previous escalations. Appetite suppression now well established. | Escalation approved. Side effects reviewed. |
| 10–12 | 7.5mg | Visible changes — clothes fitting differently. Cumulative loss typically 6–12 kg. Energy noticeably better. Possible early hair shedding. | Month 3 check-in. Body composition discussion. Hair/protein review if needed. |
| 13 | 10mg (if escalated) | Fourth escalation. GI effects brief. Many patients describe this as the dose where treatment feels “normal” — effective but comfortable. | Escalation approved. Discussion of whether 10mg may be optimal maintenance. |
| 14–16 | 10mg | Significant cumulative weight loss (10–17 kg typically). Physical activity much easier. Blood pressure and metabolic markers improving. | Month 4 check-in. Consideration of whether to maintain at 10mg or continue escalating. |
| 17 | 12.5mg (if escalated) | Fifth escalation. Brief GI effects. Approaching maximum efficacy range. | Escalation approved. |
| 18–20 | 12.5mg | Cumulative loss typically 15–22 kg. Significant health improvements visible. Many patients discuss with clinician whether 12.5mg is their optimal dose. | Month 5 check-in. Maintenance dose assessment. |
| 21 | 15mg (if escalated) | Final escalation. Brief GI effects. Now at maximum licensed dose. | Final escalation approved. Long-term maintenance plan discussed. |
| 22–24+ | 15mg | Maximum efficacy accumulating over following 12+ months. Side effects at established dose typically minimal. Weight loss continues toward the 22.5% SURMOUNT-1 average. | Monthly check-ins continue throughout maintenance. |
5 Common Dosing Mistakes and How to Avoid Them
Mistake 1: Stopping after one difficult week
The most common reason patients discontinue Mounjaro is experiencing side effects in the first week of a new dose and concluding the medication does not suit them. In the vast majority of cases, the side effects resolve within 7–10 days as the body adapts. Stopping at day 5 of 5mg after feeling nauseated is throwing away the entire investment in the 4 weeks on 2.5mg that preceded it. Contact your Slinic clinician about side effects before stopping — almost always a dose reduction or dietary adjustment resolves the issue.
Mistake 2: Escalating too quickly
Some patients, eager for faster results, request escalation before their 4-week minimum. Premature escalation significantly amplifies side effects and reduces adherence. The 4-week minimum is not bureaucratic — it reflects the physiological time needed for the body to adapt to GLP-1 receptor activation at each dose level. At Slinic, every escalation is reviewed by a registered prescriber who specifically checks that the minimum duration and tolerance criteria are met.
Mistake 3: Assuming maximum dose means maximum effort
Some patients feel that staying at 10mg or 12.5mg represents a failure or insufficient commitment to treatment. It does not. If you are losing weight consistently and tolerating the current dose well, that dose may be your optimal maintenance dose — producing results that, by any historical measure, are extraordinary. The goal is clinical outcomes, not reaching the highest number on the pen.
Mistake 4: Not rotating injection sites
Injecting in the same spot repeatedly causes lipohypertrophy — hardened fatty tissue under the skin that absorbs the medication less consistently, reducing efficacy and causing discomfort. Use a different location every week: cycle through the abdomen, both outer thighs, and both upper arms. Keep a simple rotation log if you find it easy to forget.
Mistake 5: Forgetting protein during dose escalation
Mounjaro suppresses appetite so effectively that many patients eat very little — but eat without deliberate attention to protein content. Rapid weight loss combined with low protein intake accelerates lean muscle loss, hair thinning, and fatigue. Every dose escalation should be accompanied by a conscious check: “Am I eating enough protein?” The target is 1.2–1.6g per kilogram of target body weight per day at all times during treatment.
When and How to Reduce Your Dose
Dose reduction is an underused and underappreciated tool in Mounjaro management. When side effects are unacceptable at a particular dose, reducing back to the previous dose is almost always preferable to stopping entirely.
How dose reduction works at Slinic
Contact your Slinic clinician — by message or phone between your monthly appointments if side effects are significant. We will review whether a dose reduction is appropriate, approve the reduction, and dispatch the lower-dose pen. A patient who successfully maintains at 7.5mg long-term is producing better clinical outcomes than a patient who stopped at 10mg because of unmanaged nausea.
Dose reduction does not reset your progress
Returning from 10mg to 7.5mg does not erase the weight lost on 10mg. The metabolic changes, reduced adiposity, and improved health markers that occurred at 10mg persist. The dose reduction simply means you are continuing treatment at the highest dose you can comfortably tolerate — which is the right clinical approach.
After You Reach Your Weight Goal: Maintenance Dosing
Reaching your target weight is a clinical milestone — but the conversation about what happens next should happen well before you reach it. Here is the clinical framework for long-term maintenance dosing.
Option 1: Continue at current maintenance dose
The most straightforward approach. SURMOUNT-4 data shows that continuing tirzepatide at the maximum tolerated dose maintains weight loss. Monthly check-ins continue. Cost is the primary consideration for long-term maintenance at higher doses.
Option 2: Reduce to a lower maintenance dose
Some patients find that a lower dose (e.g. 10mg rather than 15mg) is sufficient to maintain their weight once the initial loss is complete. Your Slinic clinician can guide a gradual reduction trial — monitoring weight stability at each lower dose before reducing further.
Option 3: Extend injection intervals
For some patients at maintenance, extending the injection interval from every 7 days to every 10–14 days may maintain weight stability. This is not a standard licensed approach and requires careful monitoring — discuss with your Slinic clinician.
Option 4: Gradual tapering and stopping
Patients who have established strong dietary and lifestyle habits during treatment may attempt gradual tapering — reducing dose and then interval over several months — to assess whether the habits alone can maintain weight. This is the most clinically ambitious approach and requires the closest monitoring. SURMOUNT-4 data shows that most patients who stop abruptly regain significant weight — tapering gives a better chance of sustainable maintenance.
Frequently Asked Questions
What to Eat (and Avoid) Around Injection Day
The relationship between your diet and your injection day significantly affects how you experience each dose. Here is the complete dietary protocol Slinic recommends around injection day.
Injection day and 48 hours after: the gentle protocol
- Eat very small meals — 4–5 times per day rather than 3 large meals
- Avoid all fried, greasy, and high-fat foods — these are the biggest nausea triggers
- Avoid alcohol entirely — particularly for the first 48 hours after each new dose
- Avoid spicy or very rich food — treat your stomach as sensitive for the first 48 hours
- Stay well hydrated — sip water, herbal tea, and diluted juice throughout the day
- Try injecting in the evening — many patients find that doing so means the peak nausea period (first 12–24 hours) occurs during sleep
Days 3–7: gradual return to normal eating
- Gradually introduce normal food as tolerance returns
- Continue with smaller portions than pre-Mounjaro — the medication is doing its job
- Prioritise protein at every meal — chicken, fish, eggs, legumes, dairy
- Include plenty of vegetables — both for nutrition and gut health
Days 7+ (at established dose): sustainable eating pattern
- Protein-first approach at every meal — fill half your plate with protein before adding carbohydrates
- Small, satisfying meals — the medication has reduced your capacity; honour that by eating until satisfied, not until full
- Avoid eating through nausea — if the medication is suppressing appetite, do not eat just because it is mealtime. Eat when hungry; stop when satisfied.
- Maintain adequate calories — aim for at least 1,200–1,400 calories per day minimum to prevent excessive lean mass loss
Exercise and Mounjaro: How Physical Activity Interacts With Your Dosing
Exercise does not need to be timed around Mounjaro injections specifically, but there are important interactions between physical activity and your dosing outcomes that are worth understanding.
Resistance training timing
There is no clinical reason to avoid exercise around injection day. However, if you experience significant nausea on injection day, high-intensity exercise may feel uncomfortable. Light walking is fine and often helpful for gut motility. Save heavier resistance training for days when you feel well — typically days 3–7 of each dose cycle.
Building resistance training into your treatment
The most clinically important exercise intervention on Mounjaro is resistance training — not cardiovascular exercise. This is because the primary risk of rapid weight loss is lean muscle loss, and resistance training is the most effective countermeasure. Aim for 2–3 sessions per week of weights, resistance bands, or bodyweight exercises (squats, lunges, push-ups, rows). Even modest resistance training produces significant lean mass preservation during Mounjaro treatment.
Exercise and dose escalation
Many patients find that each dose escalation is accompanied by temporarily reduced exercise tolerance due to nausea or fatigue. This is normal and temporary. Maintain light activity during the first week of each new dose. Return to your normal exercise routine as the new dose settles — typically within 7–10 days.
More Dosing Questions Answered
Average Weight Loss by Dose: The Full Data
Here is the complete efficacy picture by dose from the SURMOUNT programme — helping you understand what clinical outcomes to expect at each stage of your treatment and why escalation produces better results.
| Dose | Average weight loss (SURMOUNT-1) | % patients losing 5%+ | % patients losing 10%+ | % patients losing 20%+ | Slinic price |
|---|---|---|---|---|---|
| 5mg | 15.0% | 85% | 69% | 28% | £165.00 |
| 10mg | 19.5% | 89% | 77% | 47% | £255.00 |
| 15mg | 22.5% | 91% | 79% | 57% | £285.00 |
| Placebo | 2.4% | 35% | 19% | 6% | — |
The dose-response relationship is clear and consistent: higher doses produce greater average weight loss and a higher proportion of patients achieving significant outcomes. The 5mg vs 15mg difference — 15% vs 22.5% — may seem modest in percentage terms, but represents meaningful absolute differences. For a patient starting at 100 kg, 15mg produces an average of 7.5 kg more weight loss than 5mg. For a patient starting at 150 kg, that difference grows to 11.3 kg.
The Clinical Science Behind the Schedule
Understanding why the Mounjaro dosing protocol works the way it does helps patients trust the process, particularly during the difficult first weeks of a new dose.
Pharmacokinetic basis for 4-week intervals
Tirzepatide has a half-life of approximately 5 days, meaning it takes approximately 4–5 half-lives (20–25 days, approximately 4 weeks) to reach steady-state plasma concentrations at a given dose. The 4-week minimum at each dose ensures that your body has reached stable, consistent drug levels before escalating. Escalating sooner would mean the next dose starts before the current one has even reached its full effect — producing unpredictable pharmacodynamics and worse side effects.
The GLP-1/GIP receptor adaptation mechanism
GLP-1 and GIP receptors partially downregulate (reduce their sensitivity) in response to sustained agonist exposure. This receptor adaptation is why side effects reduce significantly over the 4 weeks at each dose — the receptors have adjusted their response to the new drug level. When the dose is increased, the newly elevated drug level stimulates the receptors beyond their adapted threshold — producing a brief re-emergence of side effects until adaptation occurs again at the new level.
This mechanism explains why each dose escalation produces a brief return of nausea (typically shorter and milder than the previous escalation) — and why the brief discomfort is a sign that the new dose level is pharmacologically active, not a sign that the medication does not suit you.
Why the 2.5mg starting dose produces minimal weight loss
The 2.5mg dose was specifically designed for tolerability, not efficacy. At 2.5mg, tirzepatide occupies GLP-1 and GIP receptors at a sub-therapeutic level — enough to begin the adaptation process without producing the full appetite suppression and metabolic effects of therapeutic doses. Clinical trial data shows very modest weight loss at 2.5mg as a standalone dose. Its purpose is purely as an on-ramp to the therapeutic doses that follow.
Ordering Mounjaro at Slinic: Timing Your Monthly Order
To avoid gaps in treatment, it is important to order your next Mounjaro pen before your current one runs out. Here is the optimal ordering workflow at Slinic.
| When you should order | Timing from last injection | Why |
|---|---|---|
| Standard reorder | Week 3 (day 15–18 after first injection from current pen) | Allows time for monthly check-in review, prescription issue, and delivery before your 4th injection is due |
| If escalating to next dose | Week 3 — at your monthly check-in | Escalation must be clinically approved before the new dose pen is dispatched. Check-in at week 4 means you may need to wait — order prompt. |
| Latest acceptable order | Week 4 (day 22–25) | Still usually possible to receive before injection day 29, but cutting it close with weekend or bank holiday deliveries |
Slinic dispatches within 24 hours of approval with next-day cold-chain delivery in most areas. However, ordering early is always the safest approach — a 1–2 day gap in a weekly medication is clinically minor, but a 7+ day gap requires a conversation about whether to restart the dose protocol. See our restart guide for full detail on gaps in treatment.
Your Monthly Reorder Checklist
Before each monthly Slinic reorder, run through this quick checklist to ensure your dose management is on track:
- How many weeks at current dose? Minimum 4 before escalating
- How were side effects this month? If significant, discuss before escalating
- Is weight loss continuing or has it plateaued? Plateau after 4+ weeks signals escalation time
- Are you eating enough protein? Target 1.2-1.6g/kg target body weight
- Are you eating enough overall? Minimum 1,200 calories per day
- Any new medications or health changes? Relevant to monthly check-in
Your Slinic monthly check-in reviews all of these before approving your next dose. For the complete cost breakdown of your treatment journey, see our Mounjaro price guide.
Wegovy Dosing Schedule vs Mounjaro: Full Comparison
| Month | Mounjaro dose | Wegovy dose | Mounjaro (Slinic) | Wegovy (Slinic) |
|---|---|---|---|---|
| Month 1 | 2.5mg | 0.25mg | £139.00 | £99.99 |
| Month 2 | 5mg | 0.5mg | £165.00 | £109.99 |
| Month 3 | 7.5mg | 1mg | £225.00 | £114.99 |
| Month 4 | 10mg | 1.7mg | £255.00 | £159.99 |
| Month 5 | 12.5mg | 2.4mg (maintenance) | £275.00 | £209.99 |
| Month 6+ | 15mg (maintenance) | 2.4mg or 7.2mg step-up | £285.00 | £209.99+ |
Mounjaro has 6 dose escalation steps to maximum (5 months); Wegovy has 4 to standard maintenance (4 months). Mounjaro consistently costs more per pen but produces higher average weight loss. Wegovy’s 7.2mg step-up dose was MHRA approved January 2026 and narrows the efficacy gap to approximately 1.8 percentage points. See our Mounjaro vs Wegovy guide for the full comparison.
The Mounjaro Dosing Schedule: Quick Reference Summary
For patients who want the key facts without reading the full guide:
- 6 doses: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg
- Once weekly injection: Same day each week, any time of day
- Minimum 4 weeks at each dose before escalating
- 2.5mg is an initiation dose — not a therapeutic weight loss dose
- 5mg is the first therapeutic dose — significant appetite suppression begins here
- 10mg produces 19.5% average weight loss — many patients maintain here
- 15mg produces 22.5% average weight loss — maximum dose, measured at 72 weeks
- Side effects peak in week 1 of each new dose, then reduce. This is expected, normal, and temporary.
- If you miss a dose: take within 4 days, or skip and resume normal schedule
- If away more than 4 weeks: restart at 2.5mg
- Every Slinic escalation is clinically reviewed before dispatch
Practical Tips From 25 Years of Clinical Experience
As someone who reviews Mounjaro dose escalations every day at Slinic, here are the practical insights I wish every patient had before they started.
1. Inject at the same time on your chosen day
While Mounjaro does not need to be injected at the exact same time each week, consistency helps you remember. Many patients attach injection day to an existing weekly routine — Sunday morning, Friday evening, Tuesday lunchtime. Find an anchor and stick to it.
2. Keep a simple progress diary
Note your weight each week on the same day, before eating. Note any side effects. This gives you objective data for your monthly check-in and makes patterns clear — including if you are under-eating, experiencing unexplained side effects, or plateauing at a dose that might warrant escalation discussion.
3. Don’t compare your progress to social media
Social media Mounjaro before-and-after content is heavily self-selected — patients who achieve extraordinary results quickly are far more likely to post than those progressing steadily within the clinical average. The SURMOUNT-1 average of 22.5% at 72 weeks is derived from 2,539 patients — a far more reliable benchmark than the curated posts you see online.
4. Use your monthly check-in as a two-way clinical conversation
Slinic’s monthly check-in is not just an administrative approval step — it is a clinical consultation. Come with questions. Raise concerns. Ask about your diet, your protein intake, your side effect pattern. The prescriber reviewing your case has clinical experience of hundreds of Mounjaro patients and can provide personalised guidance that goes far beyond just approving your next dose.
5. Be patient with slow months
Weight loss on Mounjaro is not linear. Months of slower progress are normal — often reflecting fluid retention changes, hormonal fluctuations, or plateaus that precede a period of faster loss. A slow month at 7.5mg does not mean the medication is not working. It means you are building toward the sustained loss that produces the results SURMOUNT-1 documented over 72 weeks. Consistency and clinical support — not frustration-driven stopping — produce the best outcomes.
The dosing schedule is the structure. The clinical support is what makes the difference. Every Slinic patient gets both — a clinically reviewed escalation protocol and a prescriber who knows their history at every monthly check-in. Start your free eligibility assessment at slinic.co.uk.
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM, 2022.
- Electronic Medicines Compendium. Mounjaro KwikPen Summary of Product Characteristics. 2026.
- MHRA Drug Safety Update. Tirzepatide. January 2025. gov.uk
- NICE TA1026 — Tirzepatide for managing overweight and obesity. 2025.
Related Guides
GuideMounjaro Side Effects: Complete Guide
BlogMounjaro Before and After: Real Results
BlogCheapest Mounjaro UK 2026
GuideRestarting Mounjaro After a Break
GuideMounjaro vs Wegovy Comparison
